Eisler Capital (US)’s AbbVie ABBV Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2024
Q3
$47M Sell
238,100
-45,200
-16% -$8.44M 1.01% 13
2024
Q2
$48.6M Buy
283,300
+166,800
+143% +$27.6M 0.87% 17
2024
Q1
$21.2M Sell
116,500
-12,700
-10% -$2.19M 0.53% 29
2023
Q4
$20M Buy
129,200
+79,200
+158% +$11.5M 0.63% 35
2023
Q3
$7.45M Sell
50,000
-41,400
-45% -$6.08M 0.19% 104
2023
Q2
$12.3M Buy
91,400
+48,900
+115% +$7.17M 0.43% 34
2023
Q1
$6.77M Buy
+42,500
New +$6.5M 0.54% 47

Other funds holding ABBV

Eisler Capital (US)'s ABBV Position: Q3 2024 in Review

Eisler Capital (US) reduced its AbbVie (ABBV) stake by 62% in Q3 2024, selling an estimated $2.83M and leaving 9,297 shares worth $1.84M. The position accounts for 0.04% of the portfolio, ranked #329.

Eisler Capital (US) first reported a position in ABBV in Q1 2023 and has held it in 5 quarters since. The position peaked at $5.72M in Q2 2023. 3,500 funds tracked by Wall St. Rank hold ABBV as of Q3 2024.

  • Eisler Capital (US) held 9,297 shares of AbbVie worth $1.84M as of Q3 2024.
  • Eisler Capital (US) sold 15,170 AbbVie shares in Q3 2024, an estimated $2.83M.
  • AbbVie made up 0.04% of Eisler Capital (US)'s portfolio in Q3 2024, its #329 holding.
  • Eisler Capital (US) first reported a position in AbbVie in Q1 2023 and has held it in 5 quarters since.
  • Eisler Capital (US)'s AbbVie position peaked at $5.72M in Q2 2023.
  • 3,500 funds tracked by Wall St. Rank held AbbVie as of Q3 2024.

Based on Eisler Capital (US)'s 13F filing for Q3 2024, filed 14 Nov 2024.